ACIU logo

AC Immune SA

ACIU

ACIU: AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

more

Show ACIU Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recent trades of ACIU by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard

Quarterly net insider trading by ACIU's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates Jun. 27, 2023
  • Patent Title: Method of safe administration of phosphorylated tau peptide vaccine Jun. 27, 2023
  • Patent Title: Bicyclic compounds for diagnosis and therapy Apr. 11, 2023
  • Patent Title: Anti-tau antibodies and methods of use Jan. 17, 2023
  • Patent Title: Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy Dec. 27, 2022
  • Patent Title: Misfolded tdp-43 binding molecules Oct. 11, 2022
  • Patent Title: Anti-tau antibodies and methods of use Aug. 30, 2022
  • Patent Title: Anti-tau antibodies and methods of use Jun. 07, 2022
  • Patent Title: Compositions of phosphorylated tau peptides and uses thereof Sep. 21, 2021
  • Patent Title: Anti-tau antibodies and methods of use Nov. 17, 2020
  • Patent Title: Anti-abeta therapeutic vaccines Nov. 10, 2020
  • Patent Title: Anti-tau antibodies and methods of use Jul. 14, 2020
  • Patent Title: Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins May. 26, 2020
  • Patent Title: Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins Dec. 10, 2019
  • Patent Title: Antibodies obtainable using supramolecular constructs May. 22, 2018
  • Patent Title: Vaccine engineering Mar. 22, 2016
  • Patent Title: Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins Dec. 29, 2015
  • Patent Title: Method for improving memory in ad patients Jan. 06, 2015
  • Patent Title: 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system Dec. 23, 2014
  • Patent Title: Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins Mar. 18, 2014
  • Patent Title: Methods and compositions comprising supramolecular constructs Mar. 04, 2014
  • Patent Title: Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers Apr. 02, 2013
  • Patent Title: Humanized anti-beta-amyloid antibody Feb. 22, 2011
  • Patent Title: Therapeutic vaccine Oct. 05, 2010
  • Patent Title: Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers Oct. 05, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of ACIU in WallStreetBets Daily Discussion

ACIU News

Recent insights relating to ACIU

CNBC Recommendations

Recent picks made for ACIU stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ACIU

Corporate Flights

Flights by private jets registered to ACIU